Patents by Inventor Carylinda Serna

Carylinda Serna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mucin-associated surface protein as a vaccine against chagas disease
    Patent number: 10279023
    Abstract: Use of synthetic peptides derived from Trypanosoma cruzi antigens and their use in vaccination against trypomastigote infection and Chagas disease. T. cruzi uses several surface proteins to invade the host. In their role of protection, the surface protients ensure the targeting and invasion of specific cells or tissues. A conserved region in the family of mucin-associated surface proteins (MASP) was used to analyze the expression of MASP at different points of invasion and proved to be important for host cell invasion, thus suggesting MASP as a candidate for vaccine development. A synthetic peptide, MASPsyn, was studied and showed efficacy in stimulating antibody and cytokine production necessary for resistance against the parasite.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: May 7, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Rosa A. Maldonado, Carylinda Serna, Igor C. Almeida
  • Mucin-Associated Surface Protein as a Vaccine Against Chagas Disease
    Publication number: 20170157227
    Abstract: Use of synthetic peptides derived from Trypanosoma cruzi antigens and their use in vaccination against trypomastigote infection and Chagas disease. T. cruzi uses several surface proteins to invade the host. In their role of protection, the surface protients ensure the targeting and invasion of specific cells or tissues. A conserved region in the family of mucin-associated surface proteins (MASP) was used to analyze the expression of MASP at different points of invasion and proved to be important for host cell invasion, thus suggesting MASP as a candidate for vaccine development. A synthetic peptide, MASPsyn, was studied and showed efficacy in stimulating antibody and cytokine production necessary for resistance against the parasite.
    Type: Application
    Filed: February 13, 2017
    Publication date: June 8, 2017
    Inventors: Rosa A. Maldonado, Carylinda Serna, Irog C. Almeida
  • Mucin-associated surface protein as vaccine against Chagas disease
    Patent number: 9566320
    Abstract: Use of synthetic peptides derived from Trypanosoma cruzi antigens and their use in vaccination against trypomastigote infection and Chagas disease. T. cruzi uses several surface proteins to invade the host. In their role of protection, the surface protients ensure the targeting and invasion of specific cells or tissues. A conserved region in the family of mucin-associated surface proteins (MASP) was used to analyze the expression of MASP at different points of invasion and proved to be important for host cell invasion, thus suggesting MASP as a candidate for vaccine development. A synthetic peptide, MASPsyn, was studied and showed efficacy in stimulating antibody and cytokine production necessary for resistance against the parasite.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: February 14, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Rosa A. Maldonado, Carylinda Serna, Igor C. Almeida
  • MUCIN-ASSOCIATED SURFACE PROTEIN AS VACCINE AGAINST CHAGAS DISEASE
    Publication number: 20150086583
    Abstract: Use of synthetic peptides derived from Trypanosoma cruzi antigens and their use in vaccination against trypomastigote infection and Chagas disease. T. cruzi uses several surface proteins to invade the host. In their role of protection, the surface protients ensure the targeting and invasion of specific cells or tissues. A conserved region in the family of mucin-associated surface proteins (MASP) was used to analyze the expression of MASP at different points of invasion and proved to be important for host cell invasion, thus suggesting MASP as a candidate for vaccine development. A synthetic peptide, MASPsyn, was studied and showed efficacy in stimulating antibody and cytokine production necessary for resistance against the parasite.
    Type: Application
    Filed: September 24, 2014
    Publication date: March 26, 2015
    Inventors: Rosa A. Maldonado, Carylinda Serna, Igor C. Almeida